Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis

J Clin Rheumatol. 2021 Dec 1;27(8S):S574-S577. doi: 10.1097/RHU.0000000000000984.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Autoantibodies / immunology
  • Dermatomyositis* / complications
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Humans
  • Interferon-Induced Helicase, IFIH1 / immunology
  • Lung Diseases, Interstitial* / diagnosis
  • Lung Diseases, Interstitial* / drug therapy
  • Male
  • Mediastinal Emphysema*
  • Piperidines / therapeutic use
  • Pyrimidines / therapeutic use

Substances

  • Autoantibodies
  • Piperidines
  • Pyrimidines
  • tofacitinib
  • Interferon-Induced Helicase, IFIH1